Pharmacogenetic dissection of neural mechanisms underlying the regulation of sleep-wakefulness using DREADDs by Mieda Michihiro & Sakurai Takeshi
Pharmacogenetic dissection of neural
mechanisms underlying the regulation of
sleep-wakefulness using DREADDs
著者 Mieda Michihiro, Sakurai Takeshi
journal or
publication title
Designer Receptors Exclusively Activated by
Des gn r Drugs
volume 108






Pharmacogenetic dissection of neural mechanisms underlying the regulation of 
sleep/wakefulness using DREADDs 
 
Michihiro Mieda and Takeshi Sakurai 
Department of Molecular Neuroscience and Integrative Physiology, Faculty of 
Medicine, Kanazawa University, Kanazawa, Ishikawa 920-8640, Japan 
 
Abstract 
Sleep and wakefulness are controlled by a complex network of neurons harboring 
diverse neurochemical characteristics, including glutamatergic, GABAergic, 
monoaminergic, cholinergic, and peptidergic neurons. To understand the precise role of 
each type of neuron in this circuit, it is useful to artificially manipulate the activity of a 
particular type of neuron to see its effect on behavior. The DREADD system has made 
such a strategy possible. Here, we review our recent work using DREADD to 
pharmacogenetically dissect neural mechanisms regulating sleep/wakefulness, describe 
the protocol we used, and discuss the technical aspects of our studies.  
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1. Introduction 
Designer receptors exclusively activated by designer drugs (DREADD) are artificially 
generated mutants of human muscarinic receptors that lose the ability to bind natural 
ligands, acetylcholine, while they gain the ability to be activated by the otherwise 
pharmacologically inert ligand clozapine-N-oxide (CNO) with nanomolar potency (1, 2). 
The stimulatory DREADD, designated “hM3Dq,” couples with the Gq pathway to 
depolarize neurons, while the inhibitory DREADD, “hM4Di,” couples with the Gi/o 
pathway to hyperpolarize neurons. Therefore, in combination with genetic techniques to 
target expression of exogenous genes, DREADDs function as powerful tools of 
neuroscience research to artificially manipulate the activity of a certain population of 
neurons to reveal its physiological and pathological roles. 
   Compared to optogenetics (3), which utilizes photoactivatable cation channels, ion 
pumps, or GPCRs, which manipulate neural activities, the time resolution of DREADD 
technology is limited. On the other hand, it is less invasive and its effects last for longer 
periods, which may be suitable for studying events occurring on a time scale of minutes 
to hours, such as sleep/wakefulness cycles. In addition, since CNO is a stable substance 
that can cross the blood brain barrier, it can be readily administered intraperitoneally 
(i.p.) or orally while only minimally interfering with the behavioral state in 
freely-moving animals. 
   We have been studying the neural mechanisms underlying the regulation of 
sleep/wakefulness since our discovery of the neuropeptide orexin (4, 5)(further 
explained later). Proper wakefulness and vigilance are essential for us to behave in an 
appropriate manner, while sleep is vital for the normal function and homeostasis of our 
brains, as well as for efficient memory formation. Thus, understanding the regulation of 
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the sleep/wakefulness cycle is of tremendous importance. Since the development of 
DREADD technology by Dr. Bryan Roth’s group at the University of North Carolina (1, 
2), we have utilized DREADD technology to dissect neural circuits regulating the 
vigilance states. We so far have demonstrated (i) that changes in the activity of orexin 
neurons can alter the behavioral state of animals (6), (ii) that activation of dorsal raphe 
(DR) serotonergic neurons and locus coeruleous (LC) noradrenergic neurons suppress 
cataplexy and fragmentation of wakefulness, respectively, in narcoleptic mice (7), and 
(iii) that stimulation of GABAergic neurons in the preoptic area (POA) leads to an 
increase in the amount of non-rapid eye movement (NREM) sleep (8). These findings 
will be described below in more detail. 
 
2. Pharmacogenetic Modulation of Orexin Neurons Alters Sleep/Wakefulness 
States in Mice (6) 
The neuropeptides orexin A and orexin B, also called hypocretin 1 and hypocretin 2, are 
produced by cleavage of a single precursor polypeptide, prepro-orexin, in neurons 
located in the lateral hypothalamic area (LHA) (5, 9). These neuropeptides act on G 
protein-coupled receptors, termed orexin receptors type 1 and type 2 (OX1R and 
OX2R). Intracerebroventricular administration of orexin in animals increases the 
amount of wakefulness, accompanied by decreases in the amount of both NREM and 
REM sleep (10-12). Neurons expressing orexins (orexin neurons) send projections 
throughout the brain and spinal cord, with particularly dense innervations to nuclei 
containing monoaminergic and cholinergic neurons in the hypothalamus and brainstem, 
which are implicated in the promotion of wakefulness and constitute the ascending 
reticular activating system (4, 5, 9, 13-15). In vitro slice electrophysiology studies have 
 4 
further shown that orexin increases the firing rates of monoaminergic neurons in the LC 
(16, 17), DR (18, 19), and tuberomammillary nucleus (TMN) (20-22), as well as the 
cholinergic neurons in the basal forebrain and laterodorsal tegmental nucleus (LDT) 
(23). The critical roles of orexins and orexin neurons in the consolidation of 
wakefulness are further highlighted by the fact that the disruption of orexin signaling 
results in narcolepsy in mice, rats, dogs, and humans (4, 24-29). Narcolepsy is a sleep 
disorder characterized by difficulties in maintaining prolonged episodes of wakefulness 
(30) (described in detail later). 
   Consistent with wake-promoting roles of orexin neurons, their activity increases 
during wakefulness and decreases during sleep (31-33). However, it remains unclear 
whether changes in the activity of orexin neurons result in changes of sleep/wakefulness 
states. Since orexin neurons receive input from various brain regions, including those 
involved in sleep/wakefulness regulation (34, 35), changes in their activity may occur 
secondarily to changes in sleep/wakefulness states. Alternatively, the alterations in 
activity of orexin neurons may actively affect the vigilance states of animals. 
   To address this question, we utilized DREADD technology to artificially manipulate 
the activity of orexin neurons to see its consequence on sleep/wakefulness (6). To target 
the expression of DREADDs specifically in orexin neurons, we injected recombinant 
adeno-associated virus (AAV) vectors, utilizing the flip-excision (FLEX) switch (36) 
that restores the open reading frame in a Cre-dependent manner, into the LHA of 
Orexin-Cre transgenic mice, in which Cre-recombinase is expressed exclusively in 
orexin neurons (37). The successful targeting of the expression of DREADDs in orexin 
neurons was confirmed by double-immunostaining, demonstrating that hM3Dq and 
hM4Di were expressed in 78.3% and 73.3% of orexin neurons, respectively, without 
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any ectopic expression in non-orexin neurons. 
     Stimulation by i.p CNO administration of excitatory hM3Dq expressed in orexin 
neurons significantly increased Fos expression, a marker of neuronal activity, while 
stimulation of inhibitory hM4Di in orexin neurons significantly decreased Fos 
expression in these neurons during light and dark periods, respectively. This 
demonstrates that the DREADD system can be used to manipulate the activity of orexin 
neurons. Electroencephalogram/electromyogram (EEG/EMG) recordings demonstrated 
that excitation of orexin neurons significantly increased the amount of time spent in 
wakefulness and decreased both NREM and REM sleep times, while inhibition of 
orexin neurons decreased wakefulness time and increased NREM sleep time (Fig. 1). 
These findings clearly show that changes in the activity of orexin neurons can alter the 
behavioral state of animals and also validate this novel approach for manipulating 
neuronal activity in awake, freely moving animals. 
   Artificial manipulation of the activity of orexin neurons was initially achieved by 
optogenetics: the photostimulation of orexin neurons expressing channelrhodopsin 2 
increased the probability of transition to wakefulness from either NREM or REM sleep 
(38). However, chronic photo-stimulation (15 ms pulses at 20 Hz for 10 s every minute 
for 1 h) of orexin neurons did not increase total wake time, although the number of 
NREM sleep-to-wake transitions was increased (39). This fact suggests that 
DREADD-mediated pharmacogenetic stimulation has an advantage, evoking a greater 
potent and chronic stimulation of orexin neurons than ChR2-mediated 




3. Pharmacogenetic activation of DR serotonergic and LC noradrenergic neurons 
differentially ameliorate narcolepsy in a mouse model (7) 
   As mentioned previously, the degenerative loss of orexin neurons in humans is 
associated with narcolepsy, a debilitating neurological disorder that provides a unique 
perspective on the mechanisms of sleep/wakefulness control (26-28). The narcolepsy 
syndrome consists of excessive daytime sleepiness that often results in sleep attacks 
(sudden onset of NREM sleep), cataplexy (sudden bilateral skeletal muscle weakening 
triggered by emotions without impairment of consciousness), hypnagogic hallucinations, 
and sleep paralysis. These symptoms can be divided into two independent pathological 
phenomena (30). One is the inability to maintain a consolidated waking period, 
characterized by abrupt transitions from wakefulness to NREM sleep (i.e., dysregulation 
of NREM sleep onset). This phenomenon manifests clinically as excessive daytime 
sleepiness or sleep attacks. The other key phenomenon is the pathological intrusion of 
REM sleep or REM atonia into wakefulness or at sleep onset (i.e., dysregulation of 
REM sleep onset; normal sleep is characterized by an orderly progression from 
wakefulness to NREM sleep and then to REM sleep) (30).  It is during these periods 
that patients may experience cataplexy, hypnagogic hallucinations, and sleep paralysis. 
Similarly, mice deficient in orexin signaling, such as mice lacking the 
prepro-orexin gene (Orexin-/- mice), orexin neurons (orexin/ataxin-3 mice), or orexin 
receptors (OX1R-/-;OX2R-/- mice), display a phenotype strikingly similar to human 
narcolepsy: markedly decreased duration of wakefulness episodes during the dark phase 
(i.e., inability to maintain a long waking period, or sleepiness) and abrupt behavioral 
arrests with muscle atonia (i.e., potentially cataplexy) that manifest as direct transitions 
from wakefulness to REM sleep in EEG/EMG recordings (4, 29, 40). 
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   However, the precise neural mechanisms downstream of orexin neurons, which play 
important roles in consolidating wakefulness and inhibiting inappropriate transitions 
from wakefulness to NREM or REM sleep, have remained largely unknown. In vitro 
studies have shown that orexin activates wake-active monoaminergic and cholinergic 
neurons in the hypothalamus and brainstem (16-23). However, neurons activated by the 
pharmacological application of exogenous orexin are not necessarily essential for the 
endogenous mechanisms by which orexin neurons regulate sleep/wakefulness in a 
physiological condition. In order to identify neurons that are directly activated by 
endogenous orexins and mediate their wake-stabilizing effect in a particular natural 
context, we searched for monoaminergic and cholinergic nuclei in which the focal 
rescue of orexin receptor expressions in OX1R-/-; OX2R-/- mice ameliorates their 
narcoleptic phenotype. As a result, we found that the targeted restoration of orexin 
receptor expression in the DR and in the LC of OX1R-/-; OX2R-/- mice differentially 
inhibited their cataplexy-like episodes and pathological fragmentation of wakefulness 
(i.e., sleepiness), respectively (7). The suppression of cataplexy-like episodes was 
correlated with the number of serotonergic neurons restored with orexin receptor 
expression in the DR, while the consolidation of fragmented wakefulness was correlated 
with the number of noradrenergic neurons restored in the LC. 
   To further confirm that our conclusion originated from the receptor-restoration 
experiments, we used the DREADD system to examine whether the artificial activation 
of DR serotonergic and LC noradrenergic neurons using orexin neuron-ablated 
narcoleptic mice (orexin/ataxin-3 mice)(7). In these mice, orexin neurons degenerate 
postnatally due to the transgenic expression of a truncated Machado-Joseph disease 
gene product, mimicking the pathophysiological condition of human narcolepsy (29). 
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For this purpose, we generated AAV vectors encoding hM3Dq under the control of 
either a serotonergic neuron-selective promoter (Pet1 promoter) (41) or a noradrenergic 
neurons-selective promoter (PRSx8 promoter) (42). Although the specificity of these 
neuron type-selective promoters was not perfect, causing some leaked expression, most 
of the neurons expressing hM3Dq were cells of interest. This suggests that these 
promoters were acceptable for demonstrating serotonergic or noradrenergic 
neuron-specific effects of neuronal activation mediated by hM3Dq when careful control 
experiments were combined. As described in the previous section, we could ideally 
target the hM3Dq expression in DR serotonergic and LC noradrenergic neurons by 
microinjecting AAV vectors utilizing the FLEX switch in the DR and LC of mice 
expressing Cre specifically in serotonergic neurons and noradrenergic neurons, 
respectively. However, for the purpose of this study, we needed orexin/ataxin-3 mice 
that had a Cre-expressing allele, which were laborious to obtain for our experiments. 
Thus, we considered our approach using neuron type-selective promoters in 
recombinant AAV vectors to be practical. 
   When AAV-Pet1/hM3Dq was microinjected into the DR, hM3Dq mRNA expression 
was detected in 78.4 ± 1.5% of serotonergic neurons in the DR, and 83.1 ± 1.0% of 
hM3Dq(+) cells were serotonergic (7). No hM3Dq mRNA expression was detected in 
the area surrounding the DR. I.p. administration of CNO into orexin/ataxin-3 mice 
injected with AAV-Pet1/hM3Dq in the DR immediately before the start of the dark 
period substantially reduced the frequency of and time spent in cataplexy-like episodes 
during the subsequent 6 h in the dark period (Fig. 2A). In contrast, fragmentation of 
wakefulness was not improved by CNO administration (Fig. 2B). 
   Similarly, when AAV-PRSx8/hM3Dq was microinjected into the LC, hM3Dq 
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mRNA expression was detected in 68.1 ± 3.9% of noradrenergic neurons in the LC, and 
81.1 ± 1.5% of hM3Dq(+) cells were noradrenergic (7). In these mice, the duration of 
wakefulness episodes during the subsequent 6 h of the dark period was significantly 
increased in the CNO-treated condition as compared to the saline-injected control 
condition (Fig. 2C). The total time spent in wakefulness during the same period was not 
significantly increased when CNO was administered. In contrast, the administration of 
CNO did not significantly affect the frequency of cataplexy-like episodes in these mice 
(Fig. 2D). Importantly, the wake-stabilizing effect of CNO was not observed in 
orexin/ataxin-3 mice with off-target hM3Dq expression, which have similar numbers of 
hM3Dq-expressing cells in the regions surrounding the LC but have almost no such 
cells in the LC. In addition, the wake-stabilizing effect of CNO was strongly correlated 
with the number of hM3Dq(+) noradrenergic neurons in the LC noradrenergic neurons, 
but not with the number of hM3Dq(+) non-noradrenergic neurons in any of surrounding 
areas. 
   These data suggest that the pharmacogenetic activation of DR serotonergic and LC 
noradrenergic neurons in narcoleptic mice is sufficient to significantly suppress 
cataplexy-like episodes and consolidate wakefulness, respectively (7). In addition, our 
success in improving narcoleptic symptoms by DREADD may lead to a novel type of 
gene therapy: the delivery of an artificial receptor into neurons using a viral 
vector—together with the subsequent administration of an artificial ligand for the 
receptor with the appropriate timing, in which the effectiveness, specificity, and safety 
of that artificial receptor-ligand system have been well established—can be used to 
ameliorate symptoms of interest. 
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4. Pharmacogenetic stimulation of POA GABAergic neurons increases NREM 
sleep in mice (8) 
The POA of the hypothalamus is thought to play an important role in the initiation and 
maintenance of sleep. Electrical or chemical stimulation of the lateral POA in animals 
promotes EEG slow-wave activity and sleep onset (43-46). Consistently, lesions in the 
POA have been shown to result in profound and persistent sleep loss (47, 48). The 
extracellular recording studies in vivo have identified sleep-active neurons in a region 
extending from the medial through the lateral POA (49, 50). In addition, neurons in the 
rat ventrolateral preoptic area (VLPO) and median preoptic nucleus (MPO) have been 
reported to drastically increase Fos expression following consolidated sleep (51, 52). 
     The POA sends GABAergic inhibitory projections to wake-active monoaminergic 
regions, including the LC, DR, and the TMN (52-55). The VLPO receives projections 
from wake-active monoaminergic neurons, such as TMN histaminergic, DR 
serotonergic, and LC noradrenergic neurons, and electrophysiological studies have 
demonstrated that VLPO neurons are inhibited by noradrenaline and serotonin (56). 
These facts suggest mutually inhibitory interactions between VLPO and the 
monoaminergic arousal systems (57). 
   Thus, we aimed to specifically activate GABAergic neurons in the POA using 
excitatory DREADD hM3Dq and examine its effects on sleep/wakefulness and on the 
activity of wake-promoting orexin neurons (8). For this purpose, we injected an AAV 
vector containing the inverse hM3Dq cDNA in combination with the FLEX switch into 
the POA of Gad67-Cre mice, in which GABAergic neurons specifically express Cre 
recombinase. Specific stimulations of hM3Dq-expressing GABAergic neurons in the 
POA by i.p. CNO administrations significantly increased the amount of NREM sleep, 
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regardless of whether CNO was administered during a light or dark phase (Fig. 3). We 
further confirmed direct connectivity between POA GABAergic neurons and orexin 
neurons, in addition to their widespread projections to wakefulness-related areas in the 
hypothalamus and brainstem, using channelrhodopsin 2 (ChR2) as an anterograde tracer. 
Optogenetic stimulation of the nerve terminals of POA GABAergic neurons on orexin 
neurons rapidly inhibited the activity of orexin neurons and evoked fast IPSC in slice 
preparations, and pharmacogenetic stimulation of POA GABAergic neurons in vivo 
mediated by hM3Dq significantly reduced Fos expression in orexin neurons. These 
observations suggest that activation of POA GABAergic neurons is sufficient to 
increase NREM sleep, which might be at least partly through the inhibition of orexin 
neurons (8). 
 
5. Technical considerations on the strategy of DREADD expression 
   As in the previous sections, we used recombinant AAV vectors to express 
DREADDs in the neurons of interest in the brain. Even with ubiquitous, powerful 
promoters, such as EF1α and CAG promoters, stereotaxic microinjections of AAV 
vectors can target the expression of transgenes in the areas of interest. Practically, 
however, it is difficult to perfectly restrict expression in only the small areas of interest 
in mice, often resulting in additional expression in the adjacent areas. Additionally, 
multiple types of neurons are usually intermixed within a particular brain area. Thus, 
Cre-dependent AAV expression vectors, utilizing the FLEX switch (36), are an excellent 
strategy for targeting DREADD expression, specifically in a neurochemically-defined 
neuronal population located in a particular brain area of interest when suitable 
transgenic mice expressing Cre recombinase are available. Note that specificity of Cre 
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expression is required only in the brain area of interest and its surrounding regions. 
Undesired Cre expression in the brain regions located apart from the area of interest (> 
~1mm) is of no matter, since stereotaxic injection of AAV vectors can avoid the 
infection and expression in such areas. On the other, the expression of DREADDs 
should be confirmed in every mouse that receive AAV injections because the location 
and spread of AAV infection inevitably varies among individual injected mice. 
   Alternatively, DREADDs can, of course, be expressed by generating transgenic 
mice with cell-specific promoters. It is worth noting that two useful transgenic mouse 
lines have been developed. One expresses hM3Dq specifically in tTA 
(tetracycline-controlled transactivator)-expressing cells (1), while the other expresses 
hM4Di in Cre and/or Flp recombinase-dependent manner (58). We also generated 
transgenic mice in which hM3Dq or hM4Di fused with the loxP-flanked transcriptional 
blocker are knocked-in in the Rosa26 allele so that DREAD receptors are expressed in a 
Cre-dependent manner. By using these transgenic mice in combination with other 
transgenic mice expressing tTA, Cre or Flp specifically in the neuronal population of 
interest, we can target the DREADD expression in the cells of interest with minimal 
variation of expression among individual mice. However, in these cases, systemic 
administration of CNO would result in the activation or inhibition of not only the cells 
of interest but also of other neurons expressing Cre or Flp in the regions of no interest. 
Thus, the outcomes of DREADD activation should be carefully interpreted. This 





6.1. AAV production and purification 
   First of all, it should be noted that multiple AAV vectors of DREADDs, which are 
purified and have high titer, are currently available from the Gene Therapy Center of the 
University of North Carolina at Chapel Hill (http://genetherapy.unc.edu/services.htm).  
   Viruses are produced using a triple-transfection, helper-free method in which the 
recombinant expression plasmid, containing the AAV-2 (serotype 2) inverted terminal 
repeat (ITR) sequences and an expression cassette of gene of interest, is co-transfected 
into the HEK293 cells with a helper plasmid carrying adenovirus-derived genes and a 
plasmid carrying AAV replication (rep) and capsid (cap) genes. 
 
6.2. AAV serotypes 
   There are many AAV serotypes available, each incorporating a different viral capsid 
protein and each mediating different transduction characteristics within the brain and 
peripheral tissues (61). The AAV2 serotype has been most studied and utilized as a 
recombinant vector. However, when the expression cassette flanked by AAV2 ITRs is 
cross-packaged into capsid proteins of other serotypes, the hybrid AAV vectors have 
been reported to infect neurons more efficiently as compared to AAV2 vectors. On the 
other hand, AAV2 can be relatively easily purified using a heparin-agarose column (62): 
purification of viral particles of other serotypes needs ultracentrifugation over either a 
CsCl or iodixanol gradient, which is cumbersome and expensive. Thus, we decided to 
utilize AAV2 vectors containing a mutant form of AAV2 capsid protein to increase the 
efficiency of transgene expression (kindly provided by Dr. Arun Srivastava of the 
University of Florida) (63), which retains the ability to bind to heparin for purification, 
and this was used for the three studies described above. We will describe the protocol of 
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viral production and purification in detail later. 
   Recently, it was discovered that microinjection of unpurified AAV viral solutions in 
the brain may not cause significant pathological damage to the tissue (64). Therefore, 
we are currently using unpurified AAV vectors with capsid proteins of rh10 serotype 
(65), which seem to infect neurons more efficiently than mutant AAV2.  
 
6.3. Plasmids 
   We initially constructed ITR-containing plasmids with DREADD cDNAs in 
combination with the FLEX switch by replacing ChR2::EYFP genes of pAAV-double 
floxed-hChR2(H134R)-EYFP-WPRE-pA (66), provided by Dr. Karl Deisseroth of 
Stanford University (http://www.stanford.edu/group/dlab/optogenetics/), with 
HA-hM3Dq or HA-hM4Di cDNAs derived from the plasmids 
pcDNA5/FRT-HA-hM3Dq and pcDNA5/FRT-HA-hM4Di (2), provided by Dr. Bryan 
Roth of University of North Carolina. Currently, mCherry-fusioned DREADDs have 
been developed and are available from Dr. Roth’s laboratory, which is easier than using 
HA-tagged DREADDs to detect protein expression. Therefore, we are currently using 
Cre-dependent AAV vectors expressing mCherry-fusioned DREADDs. 
   For producing AAV-2 vectors used in the studies described previously, we used 
pACG-2-Y730F (63), which contains a mutant form of AAV2 capsid protein, as the 
rep/cap plasmid. To produce AAV-rh10 vectors, we replaced pACG-2-Y730F with 
pAAV2/rh10, which contains AAV2 rep gene and AAVrh10 cap gene (available from the 
Vector Core of the University of Pennsylvania, 
http://www.med.upenn.edu/gtp/vectorcore/index.shtml). For the helper plasmid carrying 
adenoviral genes, we used pHelper (Strategene), but a similar helper plasmid 
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pAd-DeltaF6 is also available from the Vector Core of the University of Pennsylvania. 
 
6.4. HEK293 cells 
   We used 293A cells (Invitrogen), which are a subclone of the HEK293 cell line and 
were originally established for the production of recombinant adenoviral vectors. They 
grow efficiently and adhere to the culture dishes better. The commonly-used HEK293 
cell line should work for AAV production, and another subclone AAV-293, which had 
been screened for AAV production, is available from Stratagene. We have no 
information about which 293 cells are the best for the production of recombinant AAV 
vectors. Note that the following protocol is on the 293A cells. 
 
6.5. Packaging 
1. Plate ~4.5 x 106 cells per 100-mm tissue culture dish in 10 ml of DMEM medium 
24 ~ 28 hours prior to transfection. We usually prepare 10 dishes for producing 
one AAV-2 vector with a purification step (the following protocol describes the 
amount of reagents for 10 dishes). When producing AAV-rh10 vectors without 
purification, we downscale to 4 culture dishes per vector. 
2. Inspect the host cells that were split one day before; they should be approximately 
90 - 100% confluent. 
3. Add 100 μg of each of the three plasmid DNA solutions: pHelper, pACG-2-Y730F, 
and the ITR-containing expression plasmid) to 10 ml of 0.3 M CaCl2 in a 50-ml 
conical tube and mix gently. 
4. Pipet 10 ml of 2 × HBS (NaCl 8.182g, Na2HPO4 0.106g, HEPES 5.958g/500mL, 
pH7.10, filter-sterilized; adjust pH to 7.06 ~ 7.07 because filtration slightly 
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increases pH) into a second 50-ml conical tube. Add the 10-ml DNA/CaCl2 
mixture (step 3) dropwise with gentle rocking of the conical tube. Mix gently by 
inversion or by repeated pipetting. 
5. Leave the DNA/CaCl2/HBS suspension for 20 minutes at room temperature. 
6. Apply the DNA/CaCl2/HBS suspension to the dish of cells (2 ml/dish) in a 
dropwise fashion, swirling gently to distribute the DNA suspension evenly in the 
medium.  
7. Return the tissue culture dishes to the 37°C CO2 incubator overnight.  
8. At the end of the incubation period, remove the medium from the dishes and 
replace it with 10 ml/dish of fresh DMEM growth medium.  
9. Return the dishes to the 37°C incubator for an additional 2 days. 
10.  At the end of incubation, the density of cells is much higher than at transfection, 
with each cell appearing compressed. Most cells remain attached to the dishes. 
11.  Scrape and transfer the transfected cells plus DMEM growth medium to two 
50-ml conical tubes.  
12.  Collect cells by centrifugation at ~150 g for 10 minutes at room temperature. 
13.  Discard the supernatant and resuspend the cells in binding buffer (10ml of 0.15 
M NaCl, 50 mM Tris-HCl, pH 8.0). The cells can be stored frozen in the -80°C 
deep freezer for a long period before purification. 
   For production of AAV-rh10 vectors, wash cells once with PBS, pellet the 
cells, and resuspend in 400 µl (for 4 dishes) of PBS containing 1mM of MgCl2. 
The following steps (step 14~) are essentially same, except that we use 
benzonase nuclease instead of DNaseI and RNaseA, pellet cellular debris by 




14.  Subject the cell suspension to two rounds of freeze/thaw by alternating the tubes 
between the -80°C deep freezer and the 37°C water bath.  
15.  Pellet cellular debris by centrifugation at ~2,000 × g for 15 minutes.  
16.  Transfer the supernatant (~10 ml) to a fresh tube and add 40 µl of DNaseI (10 
mg/ml) and 80 µl of RNaseA (5 mg/ml). 
17.  Incubate for 30 minutes in the 37°C water bath. 
18.  Centrifuge the viral solution at ~2,000 × g for 15 minutes and transfer the 
supernatant to a fresh tube. 
19.  Add 500 µl (1/20 volume) of 10% Sodium deoxycholate to the viral solution, 
and then incubate it for 30 minutes in the 37°C water bath. 
20.  Centrifuge the viral solution at ~2,000 × g for 15 minutes and recover the 
supernatant. 
21.  Pass the viral solution through a 5 µm-syringe filter, then through a 0.4 
µm-syringe filter. 
22.  (In parallel to the treatment of the viral solution, prepare heparin-agarose resin) 
Transfer 1.5ml of Heparin-agarose suspension (Sigma) into a 15-ml conical tube 
with 5 ml of binding buffer. 
23.  Centrifuge the Heparin-agarose suspension for a minute, discard the supernatant, 
and wash the Heparin-agarose with another 5 ml of biding buffer. 
24.  Centrifuge the Heparin-agarose suspension for a minute and discard the 
supernatant. Add the viral solution prepared in Step 21 to the Heparin-agarose. 
25.  Suspend the viral solution/Heparin-agarose by rocking at 4°C. 
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26.  Transfer the viral solution/Heparin-agarose into a bio-spin column (Bio-Rad) 
and allow the column to empty by gravity flow. 
27.  Wash the Heparin-agarose resin three times with 2 ml of binding buffer. 
28.  Add 1 ml of elution buffer (0.5 M NaCl, 50 mM Tris, pH 8.0) to the resin and 
collect the eluate in a fresh tube. 
29.  Cap the tip of column, add another 1ml of elution buffer, and leave the column 
for 5 minutes. 
30.  Remove the cap at the tip of column and collect the eluate in the tube. 
31.  Add another 1ml of elution buffer to the column and collect the eluate (total 
~3ml of eluate). 
 
6.7. Dialysis and Concentration 
32.  Transfer the eluate containing AAV particles into a Slide-A-Lyzer Dialysis 
Cassette (Pierce, Slide-A-Lyzer Gamma Irradiated Dialysis Cassete 
Extra-strength, 0.5-3ml, 10,000 MWCO) and dyalize it against 1L of PBS 
(KH2PO4 0.144g, NaCl 9.0g, Na2HPO4.12H2O 1.062g, MgCl2.6H2O 0.10g, 
CaCl2.2H2O 0.133g/1L, pH7.4, filter sterilized; adjust pH to 7.36 ~ 7.37 because 
filtration slightly increases pH) overnight at 4°C. Change the dialysate once. 
33.  Concentrate the dialyzed viral solution by placing the Dialysis Cassette into the 
Slide-A-Lyzer Concentration Solution (Pierce) inside the resealable plastic bag 
and rock the bag for 60 ~ 90 minutes at 4°C.  
34.  Recover the concentrated viral solution from the cassette, make aliquots, freeze 
rapidly, and store at -80°C. Typically, we can obtain 400~800 µl of concentrated 
viral solution. 
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35. Measure the titer of the viral stocks by real-time PCR. Prior to PCR, 2 µl of viral 
solution is pre-treated in 100 µl of 50 mM NaOH for 30 minutes at 95°C to 
liberate AAV genome DNA from viral particles, followed by neutralization by 
adding 8.4 µl of 1M Tris-HCl pH8.0. Further dilute the DNA solution 20-fold 
and use 2.5µl of diluted solution per PCR reaction in 10µl. Use serial dilution of 
ITR-containing plasmid as the reference to write standard curves for calculating 
viral titers. We amplify the WPRE sequence, which is contained in most of the 
recombinant AAV vectors we generated, by Roche LightCycler 480 using two 
primers 5’-actgtgtttgctgacgcaac-3’ and 5’-agcgaaagtcccggaaag -3’ in combination 
with an universal probe #77. When using other types of real-time PCR reagents 
and cyclers, primer sequences may need to be optimized. Typically, we obtain 
final viral stocks with the titer of 2 x 1012 ~ 2 x 1013 genome copies/ml. 
 
6.8. Surgery of mice 
Male mice (10 to 20 weeks old) were anesthetized with sodium pentobarbital (0.5 
mg/kg, i.p.) and positioned in a stereotaxic frame (David Kopf Instruments). For 
microinjection of viral solutions, we used the Hamilton syringe (10 µl, 701RN) in 
combination with a 33-gage needle (1 inch long). 
   The coordinates for injection sites depend on the location and size of the area of 
interest. The following are the coordinates we used, with reference to the bregma; 
anteroposterior, AP (“-“ means posterior to the bregma); medilateral, ML (“±” means 
bilateral injections); dorsoventral, DV (“-“ means ventral to the skull surface):  
LHA (targeting orexin neurons)(6): AP, -1.4 mm; ML, ±0.9 mm; DV, -5.5 mm; and AP, 
-1.8 mm; ML, ±0.9 mm; DV, -5.7 mm. Since orexin neurons are scattered in the LHA 
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and perifornical area, we microinjected viruses in 4 sites. LC: AP, -5.4 mm; ML, ± 0.9 
mm; DV, -3.7 mm. DR: AP, -4.4 mm; ML, ± 0 mm; DV, -3.0 and -3.5 mm. TMN: AP, 
-2.5 mm; ML, ± 1.0 mm; DV, -5.6 mm. PPT: AP, -4.5 mm; ML, ± 1.0 mm; DV, -3.7 mm. 
PB: AP, –5.4 mm; ML, ± 1.0 mm bilaterally; DV, -3.5 mm (7). POA: AP, +0.3 mm; ML, 
± 0.65 mm; DV, -5.72 mm (8). Note that the coordinates of injection may need to be 
optimized for each experimenter and mouse age and strain. 
   Small holes were drilled into the skull at the position corresponding to the injection 
sites, and the needle was inserted slowly and progressively to minimize tissue damage 
until the tip of needle reaches to the injection site. Then, 0.2 ~ 1 µl of viral solution was 
delivered to each site over a 10-min period using KDS310 Nano Pump Syringe Pumps 
(KD Scientific). After 5 min of rest, the needles were slowly removed. Injection using 
33-gage stainless needles caused minimal tissue damage in most cases. However, when 
relatively small nuclei are targeted, the thickness of the needle and the volume of viral 
solution injected may cause broader infection than expected. Microinjection of smaller 
volume using fine glass micropipettes would be more suitable for finer expression, 
although targeting small volume to very restricted areas might make the targeting 
technically more difficult. From this perspective, the Cre-dependent expression system 
utilizing the FLEX switch is a useful strategy to target the expression into the cells of 
interest in spite of the broader infection of AAV vectors in the surrounding cells/areas. 
   Following virus administration, electrodes for EEG and EMG recording were 
implanted in the skull of each mouse (4, 6-8). The EEG/EMG implant was based on a 
six-pin double inline microcomputer connector, modified to form four EEG electrodes 
and two EMG wire electrodes soldered to the pins. Four holes were drilled on the skull, 
and the four arms of the EEG electrode were placed anterior and posterior to the bregma 
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(AP, +1.2 mm; ML, ±1.2 mm and AP, -1.2 mm; ML, ±1.2 mm). Stainless steel wires for 
EMG recording were bilaterally sutured to the neck muscles of each mouse, and each 
electrode was glued solidly to the skull. 
   Silicon tubes (Shinetsu Polymer, CP-N, outside diameter: 1mm, inside diameter: 
0.5mm) were implanted for remote CNO injection (6, 8). The tube was implanted 
subcutaneously from the abdominal to the neck. The tip of a 30 cm-long silicon tube 
was inserted 1 cm into the peritoneal cavity and sutured to the abdominal wall. The 
other end of the silicon tube was placed outside the body through an incision in the neck, 
and all incisions were sutured. Implanting silicon tubes minimizes the disturbance due 
to the CNO administrations. Alternatively, the CNO can be administered i.p. by 
conventional injections using syringes and needles with proper acclimations to the 
injection before the experiments, reducing the invasiveness of surgery (7). 
   All animals were then housed individually for a recovery period of at least 7 days. 
Generally, transgene expression by AAV vectors plateaued about 2 weeks after 
injection. 
 
6.9. Sleep recordings 
After the recovery period, animals were moved to a recording cage placed in an 
electrically shielded and sound-attenuated room. A cable for signal output was 
connected to the implanted electrode and animals were allowed to move freely. Signals 
were amplified through an amplifier (AB-611J, Nihon Koden, Tokyo) and digitally 
recorded on a PC using EEG/EMG recording software (Vital recorder, Kissei Comtec). 
Animals were allowed at least seven days to adapt to the recording conditions prior to 
any EEG/EMG recording session. Following the adaptation period, each animal was 
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injected with both CNO and saline on separate experimental days with at least a 2-day 
interval. The order of injection (i.e. either CNO first or saline first) should be 
randomized. EEG/EMG data were evaluated and staged for 24 hours on the day of CNO 
or saline administration. Data acquired on the day of saline administration were used as 
controls (6-8).  
 
6.10. Histological confirmation of DREADD expression 
   After EEG/EMG recordings, efficiency and specificity of DREADD expression 
should be determined histologically. Mouse brains were fixed by transcardial perfusion 
with 4% paraformaldehyde and serial coronal brain sections were prepared by standard 
procedures. Immunostaining with a mouse anti-HA antibody (Covance, 1:1000) detects 
HA-tagged DREADDs expressed at relatively high level (1, 6, 8). However, the 
sensitivity of detection is not good enough to detect low-level expression. Thus, as an 
alternative method, DREADD mRNA can be detected by nonradioisotope in situ 
hybridization using digoxigenin-labeled antisense riboprobes for DREADDs (7). Using 
mCherry-fusioned DREADDs makes it much easier to check their expression, by the 
fluorescence of mCherry or immunostaining with rabbit anti-DsRed antibody (Clontech 
632496, 1:2000).  
 
7. Conclusion 
Overall, there are clear benefits to using DREADD technology in the analysis of neural 
circuits underlying sleep/wakefulness regulation. We successfully manipulated the 
activity of neurons involved in sleep/wake regulation and detected the effects of 
manipulation. The same strategy can be applicable to other types of neurons, which may 
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lead to the understanding of the whole picture of how our vigilance states are controlled, 
and further to a novel therapeutical approach to multiple sleep disorders, such as 
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Legends to figures 
Fig. 1. Effect of stimulation of orexinergic tone by hM3Dq on vigilance states of mice 
during light and dark periods (left and right panels, respectively)(6). Hourly analysis of 
sleep/wake states in transgenic and wild-type mice, both injected with 
rAAV-DIO-HAhM3Dq after administration of CNO at ZT4 or ZT12. Amounts of 
wakefulness (Wake, upper panels), NREM sleep (middle panels), and REM sleep 
(lower panels) are shown. 
 
Fig. 2. Pharmacogenetic activation of DR serotonergic and LC noradrenergic neurons 
suppresses cataplexy-like episodes and consolidates wakefulness, respectively (7). 
Orexin/ataxin-3 mice with DR serotonergic neuron–selective (A and B) or LC 
noradrenergic neuron–selective (C and D) expression of hM3Dq were injected with 
saline or CNO. Hourly plots of number and total time of cataplexy-like episodes (A and 
C) or hourly plots of wakefulness duration and number (B and D) within 12 hours after 
administration at ZT 12 (arrows). *P < 0.05, #P < 0.01, 2-tailed Student’s paired t test. 
Values are mean ± SEM. 
 
Fig. 3. Specific pharmacogenetic stimulation of GABAergic neurons in the POA 
increased NREM sleep amount (8). Total time of wakefulness (WAKE), NREM sleep, 
and REM sleep for 3 h after CNO (or saline) administration at ZT12 (upper panels) and 
at ZT4 (lower panels). 
 



